FDA Approved: BAXDELA — Supplemental Application (Melinta Therapeutics, LLC)

View source ↗

Summary

FDA approves a supplemental application for Baxdela (delafloxacin meglumine) submitted by Melinta Therapeutics, LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Skin and Skin Structure Infections
• Community-acquired Bacterial Pneumonia

Drugs mentioned

• BAXDELA (delafloxacin meglumine)

Snippet

SUPPL AP for BAXDELA (DELAFLOXACIN MEGLUMINE)